X-Porator F1 immune cell flow cytometry transfection instrument Introduction: The X-Porator F1 immune cell flow cytometer is mainly used for: 1 New drug research and development: mainly used for small batch protein/antibody preparation, antibody drug screening, positive clone screening, etc. Provide faster and more cost-effective solutions for new drug development and antibody production enterprises. 2. Cell immunotherapy research: Scaled transient preparation of CAR-T and CAR-NK, while addressing the shortcomings of virus vector solutions, makes the process more standardized in the research and development stage. characteristic 1. Ultra high cell fluid processing capacity Cell processing solution volume 3-100ml or 1.5 × 107-1.0 × 1010 cells, scalable. 2. High transfection rate and high cell survival rate Yida's independently patented flow electrode technology can generate a uniform electric field of sufficient strength at low voltage, achieving high transfection efficiency and high cell survival rate. 3. Sterilization consumables that meet GMP standards In the GMP workshop, production, sterilization, and quality inspection are carried out according to GMP standards. 4. Special electric rotary buffer Yida specialized electroconversion buffer significantly improves cell transfection rate while better protecting cells and reducing cell mortality. Technical parameters: Cell type: eukaryotic cells (suspended) Cell density of electroporation (recommended): 1 × 108 cells/ml Single consumable treated cell fluid volume: 3-250 ml Cell fluid container specification: Corning 15ml, 50ml, 250ml centrifuge tube Flow rate: 1-50 ml/min Voltage waveform: square wave Input voltage: 210-240 VAC Output voltage: 30-600 VDC Control software: Yida X-Porator F1 special software Operating system platform: Linux Overall dimensions: width 623 × Depth 452 × 325 mm high Weight: 28 kg
Introduction: The X-Porator F1 immune cell flow cytometer is mainly used for: 1 New drug research and development: mainly used for small batch protein/antibody preparation, antibody drug screening, positive clone screening, etc. Provide faster and more cost-effective solutions for new drug development and antibody production enterprises. 2. Cell immunotherapy research: Scaled transient preparation of CAR-T and CAR-NK, while addressing the shortcomings of virus vector solutions, makes the process more standardized in the research and development stage.
